Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424731 | 0.89 | P2RY1 (0.60) | P2RY1P2RY14 | |
| SCHEMBL1424772 | 0.84 | P2RY1 (0.69) | P2RY1P2RY14 | |
| SCHEMBL1424274 | 0.83 | P2RY1 (0.66) | P2RY1P2RY14 | |
| SCHEMBL3144260 | 0.82 | P2RY1 (0.77) | P2RY1P2RY14 | |
| SCHEMBL3105408 | 0.81 | RAB9A (0.60) | P2RY1 | |
| SCHEMBL5175069 | 0.81 | P2RY1 (0.76) | P2RY1P2RY14 | |
| SCHEMBL3159568 | 0.80 | P2RY1 (0.74) | P2RY1P2RY14 | |
| SCHEMBL3159667 | 0.80 | P2RY1 (1.00) | P2RY1P2RY14 | |
| SCHEMBL1425436 | 0.80 | NPC1 (0.60) | P2RY1P2RY14 | |
| SCHEMBL3446296 | 0.80 | NPC1 (0.60) | P2RY1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | claimed |
| EP-1896417-B1 | LINEAR UREA MIMICS ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1896417-A1 | LINEAR UREA MIMICS ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002584-A1 | LINEAR UREA MIMICS ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | P2RY1 1/4885P2RY14 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.